Adela
Adela, Inc.
Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests. With a single, scalable platform, Adela can address the unmet need broadly across multiple cancers and applications.
adelabio.com · Foster City, CA
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$12.0M of $12.0M
Filed2026-10-19
Days since filing25
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-10-02
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Lindsay MateoExecutive Officer · Director
- David BonitaDirector
- Paul BrownDirector
- Daniel Diniz De CarvalhoExecutive Officer
- Anne-Renee HartmanExecutive Officer
- Maneesh JainDirector
- David ScheerExecutive Officer · Director
- Robert WeisskoffDirector
- Alan WilliamsExecutive Officer
- Abraham KometzDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$12.0M of $12.0M sold1.4 months since first sale
Prior raiseNot flaggedRaised $12.0M against a prior $5.0M$5.0M prior raise, filed 2026-04-23
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-10-202
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- Principal Data ScientistOCT 20Foster City, CA · Research & Development · open 24 days
- Associate Director, Assay Development Laboratory OperationsOCT 20Foster City, CA · Laboratory Operations · open 24 days
Also raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.